Tegoprubart preserves kidney function better than tacrolimus in first-time transplant pati
Audio narration · Coming soon
The phase 2 BESTOW trial indicates that tegoprubart, a new anti-CD40L antibody therapy, better preserves kidney function compared to tacrolimus in adults undergoing their first kidney transplant.
Why this matters
PRISM scored this story 75/100 for interest.
Originally published by gnews